FINWIRES · TerminalLIVE
FINWIRES

SHA:600085

4 stories mentioning SHA:600085Updated 29d ago

Every FINWIRES story that references SHA:600085, newest first.

Asia

Tongrentang's Subsidiary Drops Honghui Pharma Acquisition

Beijing Tongrentang's (SHA:600085) subsidiary, Beijing Tongrentang Commercial Investment Group, agreed to terminate plans to acquire Honghui Pharmaceutical (Beijing), according to a Shanghai bourse filing on Wednesday.As part of the agreement, Tongrentang Commercial will withdraw from Honghui Pharma through the latter's capital reduction, with the capital reduction consideration amounting to 104.6 million yuan.Tongrentang will no longer need to pay the equity acquisition price because it is offset by the capital reduction consideration.

SHA:600085
Asia

Beijing Tongrentang Secures Hong Kong Approval for Antelope Horn Capsules

Beijing Tongrentang (SHA:600085) unit Tongrentang Guoyao obtained Hong Kong regulatory approval to sell antelope horn powder capsules in the special administrative region.The Chinese medicine is indicated for calming liver wind, clearing vision, and cooling blood and treating conditions such as convulsions and epilepsy, according to a Wednesday filing with the Shanghai bourse.The certificate is valid through May 2031.Shares of the pharmaceutical company rose 2% in recent trade.

SHA:600085
Asia

Tongrentang's Cachet Pharmaceutical Takeover Clears Antitrust Review

Cachet Pharmaceutical (SHE:002462) said China's State Administration for Market Regulation has approved Beijing Tongrentang's (SHA:600085) acquisition of a 28.48% stake in the company, clearing the anti-monopoly review.Upon completion, Tongrentang Group will become Cachet Pharmaceutical's controlling shareholder, according to a Tuesday filing with the Shenzhen bourse.The deal involves the transfer of 83.1 million shares from China Everbright Medical and Everbright Industrial.

SHA:600085SHE:002462
Asia

Beijing Tongrentang's Attributable Profit Slides 19% in Q1

Beijing Tongrentang's (SHA:600085) attributable profit fell 19% to 471.2 million yuan in the first quarter from 582.2 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.Basic earnings per share at the traditional Chinese medicine manufacturer decreased 19% to 0.344 yuan from 0.425 yuan in the prior-year period.Operating revenue declined 12% year over year to 4.66 billion yuan from 5.28 billion yuan.

SHA:600085

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600085 in your portfolio
WheelAI
WheelAI
Analyze SHA:600085 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600085